middl
east
respiratori
syndrom
coronaviru
merscov
infect
recent
fatal
diseas
detect
first
saudi
arabia
major
case
far
occur
subsequ
spread
arabian
peninsula
neighbour
middl
eastern
countri
becam
global
concern
reach
far
korean
peninsula
februari
presenc
detect
countri
worldwid
record
case
result
death
merscov
contagi
diseas
caus
c
lineag
infect
occur
either
exposur
infect
anim
human
dromedari
camel
believ
carrier
merscov
decad
camel
middl
eastern
region
appear
zoonot
host
abl
transmit
infect
human
evid
super
spread
infect
ie
singl
patient
infect
disproportion
number
contact
merscov
therefor
healthcar
worker
provid
support
infect
patient
particularli
vulner
diseas
exhibit
wide
rang
present
diagnosi
eg
symptom
subtl
sign
pneumonia
multiorgan
failur
capac
progress
rapidli
caus
death
present
effect
vaccin
avail
prevent
fatal
infect
anim
human
studi
treatment
efficaci
merscov
infect
common
form
treatment
antivir
drug
target
specif
part
protein
merscov
known
antimerscov
neutral
monoclon
antibodi
mab
antidipeptidyl
peptidas
mab
peptid
fusion
inhibitor
sirna
other
merscov
bind
found
surfac
cell
lung
kidney
proteintarget
mab
mice
report
given
vivo
protect
merscov
nevertheless
mab
variant
includ
found
prevent
entri
cell
effect
neutralis
live
merscov
infect
mice
antagonist
target
receptorbind
domain
rbd
compet
inhibit
merscov
infect
antagonist
use
ferret
found
highli
protect
merscov
entri
multipl
rbdmab
found
elicit
protect
therapeut
abil
merscov
infect
humanis
mice
variant
well
rhesu
monkey
drug
test
human
includ
interferon
alpha
beta
antivir
nucleosid
analogu
ribavirin
serin
proteas
inhibitor
camostat
immunosuppress
cyclosporin
mycophenol
mofetil
monoclon
antibodi
broadspectrum
antivir
nitazoxanid
one
studi
multipl
regimen
test
includ
mycophenol
mofetil
interferon
alpha
beta
without
ribavirin
combin
hydrocortison
similarli
efficaci
interferonbeta
lopinavirritonavir
focu
ongo
clinic
trial
wide
test
regimen
howev
ribavirin
combin
interferon
regimen
found
effect
reduc
viru
replic
vitro
also
modul
host
respons
improv
clinic
outcom
anim
experi
clinic
outcom
merscov
patient
vari
substanti
among
previou
studi
exampl
hospit
mortal
low
one
studi
high
anoth
studi
major
studi
mortal
rang
small
sampl
size
includ
studi
like
contribut
variat
moral
estim
addit
mortal
rate
influenc
patient
demographi
eg
age
physic
condit
admiss
eg
fever
shock
organ
failur
etc
preexist
diseas
diabet
hypertens
choic
treatment
therefor
present
data
larger
clinic
studi
n
confirm
case
merscov
patient
admit
referr
hospit
alqassim
region
saudi
arabia
patient
receiv
ribavirin
plu
interferon
alpha
treatment
ascertain
hospit
mortal
assess
whether
vari
age
sex
preexist
comorbid
condit
use
medic
record
buraidah
central
hospit
bch
alqassim
region
adopt
retrospect
cohort
design
studi
bch
main
centr
region
treatment
merscov
infect
patient
refer
neighbour
secondari
hospit
eg
king
saud
hospit
unaizah
sulaiman
al
habib
buraidah
hospit
arrass
almuthnab
bukayriah
tertiari
hospit
eg
king
fahad
specialist
hospit
princ
sultan
cancer
centr
buraidah
studi
inclus
criteria
adult
year
laboratoryconfirm
merscov
infect
pcr
polymeras
chain
reaction
detect
viru
sampl
taken
respiratori
tract
patient
patient
admit
bch
exclus
criteria
suspect
case
merscov
without
confirm
diagnosi
pregnant
women
evalu
medic
record
suspect
case
merscov
exclud
one
meet
elig
criteria
major
laboratori
confirm
merscov
infect
accuraci
data
patient
refer
bch
crosscheck
patient
record
origin
hospit
total
patient
met
elig
criteria
focu
report
patient
data
came
depart
archiv
bch
remain
came
depart
infect
control
discharg
summari
bch
sinc
yet
archiv
fig
key
inform
temperatur
heart
rate
blood
pressur
respiratori
rate
miss
patient
record
infect
control
acquir
data
crosscheck
respect
patient
file
number
two
coauthor
ensur
data
duplic
exposur
variabl
treatment
regimen
ribavirin
plu
interferon
alpha
treatment
choic
bch
outcom
variabl
mortal
hospit
stay
covari
age
year
sex
male
femal
nation
saudi
nonsaudi
admiss
year
vital
sign
admiss
bodi
temperatur
heart
rate
respiratori
rate
systol
diastol
blood
pressur
merscov
associ
condit
admiss
pneumoniaacut
respiratori
distress
syndrom
septic
shockmultipl
organ
failur
abdomin
paindiarrhoea
preexist
comorbid
condit
admiss
diabet
hypertens
hepat
c
chronic
renal
failur
chronic
heart
diseas
receipt
treatment
regimen
ye
durat
hospit
stay
day
statu
discharg
aliv
dead
region
ethic
committe
alqassim
administr
bch
approv
studi
ethic
committe
requir
obtain
inform
consent
patient
sinc
examin
archiv
medic
record
direct
contact
patient
ensur
data
collector
abstract
record
patient
data
anonym
enter
analys
data
spss
version
use
twosid
test
alpha
calcul
mean
standard
deviat
continu
variabl
frequenc
categor
variabl
comorbid
condit
admiss
creat
summari
variabl
zero
one
two
condit
level
calcul
hospit
mortal
number
dead
patient
total
number
patient
admit
merscov
diagnosi
compar
hospit
mortal
patient
receiv
combin
therapi
observ
mortal
differ
pvalu
test
sampl
size
use
power
calcul
power
addit
compar
demograph
vital
sign
merscovassoci
condit
admiss
number
comorbid
condit
admiss
durat
hospit
stay
aliv
dead
hospit
discharg
use
chisquar
ttest
respect
comparison
categor
continu
variabl
final
use
binari
multipl
logist
regress
model
identifi
correl
hospit
mortal
ye
consid
age
sex
admiss
statu
number
chronic
diseas
inclus
model
model
robust
eas
interpret
made
number
chronic
diseas
variabl
binari
ye
similarli
ad
one
patient
present
abdomin
pain
diarrhoea
group
pneumonia
ard
express
associ
odd
ratio
associ
confid
interv
check
model
adequaci
hosmerlemeshow
good
fit
statist
tabl
compar
patient
vital
statu
age
length
hospit
stay
vital
sign
day
admiss
sampl
mean
standard
deviat
age
year
major
patient
male
n
saudi
citizen
n
largest
number
patient
admit
n
data
shown
hospit
mortal
mortal
among
patient
receiv
combin
therapi
mean
age
differ
vs
year
pvalu
surviv
die
durat
hospit
stay
significantli
shorter
patient
surviv
vs
day
pvalu
mean
heart
rate
vs
beat
pvalu
respiratori
rate
vs
breath
per
minut
pvalu
systol
blood
pressur
vs
mmhg
pvalu
significantli
lower
among
surviv
hand
mean
diastol
blood
pressur
significantli
higher
vs
mmhg
pvalu
comparison
dead
patient
bodi
temperatur
admiss
differ
group
vs
pvalu
tabl
compar
patient
vital
statu
relat
admiss
statu
number
diseas
hospit
arriv
intak
combin
regimen
pneumonia
common
present
manifest
n
follow
septicaemia
n
abdomin
paindiarrhoea
n
patient
surviv
like
pneumonia
vs
less
like
septic
shock
vs
admiss
patient
die
pvalu
thirtyeight
percent
patient
comorbid
condit
one
condit
two
condit
patient
surviv
less
like
two
chronic
condit
patient
die
vs
differ
statist
signific
pvalu
two
merscov
patient
receiv
combin
therapi
ribavirin
interferon
patient
surviv
like
receiv
combin
therapi
patient
die
vs
pvalu
odd
hospit
mortal
increas
merscov
patient
older
femal
exampl
femal
time
like
die
compar
male
hand
odd
death
lower
patient
least
one
chronic
condit
refer
chronic
diseas
none
associ
howev
statist
signific
p
signific
associ
patient
admit
hospit
shock
organ
failur
refer
pneumoniaard
tabl
overal
patient
die
merscov
infect
studi
group
pneumonia
acut
respiratori
distress
syndrom
common
associ
condit
merscov
patient
admit
hospit
patient
die
wors
vital
sign
heart
respiratori
rate
admiss
patient
surviv
age
sex
number
chronic
condit
significantli
associ
hospit
mortal
present
septic
shock
organ
failur
admiss
significantli
associ
hospit
mortal
novel
find
odd
ratio
report
septic
shockorgan
failur
interpret
caution
due
small
number
patient
condit
n
three
local
studi
report
hospit
mortal
intern
studi
report
mortal
among
merscov
patient
similar
found
studi
similar
mortal
studi
could
due
aggress
focus
identif
suspect
case
deal
properli
earli
accord
protocol
note
mortal
rate
studi
much
lower
studi
report
rang
report
hospit
mortal
patient
receiv
combin
therapi
ribavirin
interferon
also
compar
studi
omrani
et
al
report
mortal
among
patient
receiv
combin
therapi
mortal
rate
much
lower
report
almekhlafi
et
al
n
khaild
et
al
n
altawfiq
et
al
n
mortal
combin
therapi
found
korean
studi
choi
et
al
attribut
reduc
mortal
korean
aggress
antivir
therapi
mechan
ventilatori
support
extracorpor
membran
oxygen
variabl
mortal
studi
ribavirin
plu
interferon
partli
explain
variabl
patient
age
distribut
physic
condit
complic
merscov
time
admiss
exampl
patient
rel
younger
patient
studi
report
higher
mortal
older
studi
report
lower
mortal
multipl
studi
found
mortal
increas
substanti
age
fever
common
symptom
report
studi
affect
major
patient
patient
howev
smaller
number
patient
studi
admit
fever
defin
temperatur
could
indic
patient
came
hospit
earli
stage
infect
use
overthecount
antipyret
brought
hospit
final
studi
report
higher
mortal
combin
therapi
patient
serious
ill
infect
mani
intens
care
unit
receiv
respiratori
resuscit
intub
mechan
ventil
unfortun
lack
critic
inform
patient
therefor
abl
make
comparison
respect
hypertens
diabet
common
chronic
condit
among
patient
case
studi
well
although
find
statist
signific
direct
associ
number
chronic
condit
mortal
among
merscov
patient
similar
studi
report
higher
mortal
among
diabet
hypertens
chronic
kidney
diseas
studi
sever
limit
although
includ
rel
larg
number
particip
size
still
small
n
could
possibl
explain
nonsignific
associ
found
eg
sex
number
chronic
condit
reli
paperbas
patient
record
data
abstract
handwrit
legibl
known
handwritten
record
prone
error
electron
data
addit
patient
file
part
archiv
brief
certain
amount
inform
usabl
follow
patient
beyond
discharg
hospit
henc
could
comment
longterm
prognosi
one
studi
unlik
studi
patient
almost
exclus
receiv
treatment
one
regimen
ie
ribavirin
interferon
lack
refer
group
ie
patient
receiv
regimen
prevent
us
determin
true
efficaci
combin
therapi
final
studi
includ
patient
year
older
therefor
unabl
comment
clinic
outcom
children
adolesc
merscov
infect
sampl
merscov
patient
hospit
mortal
death
like
patient
came
hospit
septic
shock
organ
failur
unabl
compar
efficaci
combin
therapi
ribavirin
plu
interferon
mortal
absenc
patient
receiv
type
treatment
futur
studi
strive
larger
sampl
ensur
inclus
patient
receiv
dispar
therapi
collect
comprehens
inform
present
sign
symptom
coexit
condit
